Compare Novavax Inc (NVAX) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs PulteGroup, Inc. — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while PulteGroup, Inc. trades at $123.34 (market cap $23.46B). The key difference: PulteGroup, Inc. is far larger — about 18× Novavax Inc's market cap, and PulteGroup, Inc. pays a 0.84% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PHM | |
|---|---|---|
Market Cap | $1.30B | $23.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $142.56 |
52-Week Low | $6.22 | $108.65 |
Enterprise Value | $800.50M | $23.42B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
PulteGroup (PHM) trades at $124.26, down 1.44% over the past day, with technical indicators showing a bearish trend. The stock exhibits strong profitability with a net income margin of 12.14% and ROE of 16.18%, though recent quarters saw mixed earnings results. Valuation ratios remain attractive with a P/E of 11.91 and P/S of 1.44. Recent news highlights institutional activity and anticipation for Q2 2026 earnings, with the company expanding communities amid housing market challenges.
The outlook for PHM is cautiously optimistic, supported by solid fundamentals and a consensus price target of $146.50 implying 18% upside. Risks include margin pressure from high mortgage rates and competitive discounts. Analyst sentiment is balanced with 45% buy ratings, but investors should monitor earnings execution and housing demand trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
